<DOC>
	<DOCNO>NCT01751893</DOCNO>
	<brief_summary>The palmar-plantar erythrodysesthesia ( PPE ) clinical adverse event commonly occur capecitabine and/or pegylated liposomal doxorubicin treatment warrant special attention common dose-limiting toxicity . study design test effectiveness henna treatment protocol management capecitabine and/or pegylated liposomal doxorubicin induce palmar-plantar erythrodysesthesia .</brief_summary>
	<brief_title>Testing Effectiveness Henna Managing PPE</brief_title>
	<detailed_description>This randomized double-blind , placebo-controlled study 80 cancer patient receive chemotherapy treatment capecitabine and/or pegylated liposomal doxorubicin . The selection potential participant base pre-determined inclusion exclusion criterion . Patients randomly allocate either treatment group placebo group . Treatment deliver twice week assessment take place 0 , 3 , 4 5 week . The intervention group receive application henna hand and/or foot patient control group receive placebo . At baseline follow-up , patient group assess degree palmar-plantar erythrodysesthesia , Quality Life , need dose-limiting due PPE Pain intensity use standardized rating scale . Data analyse inferential descriptive statistic .</detailed_description>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lawsone</mesh_term>
	<criteria>Adult cancer patient ( &gt; 18 ) Patients receive capecitabine and/or PLD monotherapy combination agent Patients experience PPE grade 1 Willing participate Ability complete psychometric assessment . A performance status two less Eastern Cooperative Oncology Group ( ECOG ) Patients hypersensitivity natural henna . Patients preexist dermatological condition affect hand foot may limit interpretation result Patients Pyridoxine nicotine patch Patients previous history PPE Patients whose chemotherapy discontinue week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hand-foot syndrome</keyword>
	<keyword>palmar-plantar erythrodysesthesia</keyword>
	<keyword>capecitabine</keyword>
	<keyword>pegylated liposomal doxorubicin</keyword>
	<keyword>henna</keyword>
</DOC>